Boston Scientific's Neuromodulation unit posted 15% organic sales growth in Q1, driven by stronger pain management demand, the Nalu acquisition, and momentum in Intracept. The update points to healthy underlying growth and successful integration of acquired and existing therapies. The news is positive for the company, though likely more relevant to Boston Scientific shares than to the broader market.
Boston Scientific's Neuromodulation unit posted 15% organic sales growth in Q1, driven by stronger pain management demand, the Nalu acquisition, and momentum in Intracept. The update points to healthy underlying growth and successful integration of acquired and existing therapies. The news is positive for the company, though likely more relevant to Boston Scientific shares than to the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
